BCL2 and cancer: Niclosamide demonstrates promising efficacyin targeting CSCs byinhibiting key signaling pathways and downregulating critical genesand protein levels associated with metastasis, stemness, and survival.The reduction in p-STAT3, ZEB1, C-Myc, and Bcl-2 and an increase inthe pro-apoptotic marker Bax support its role as a potential therapeuticagent in cancer treatment.